Year,Frequency of observation,Reporting type,Series,Reference area,Units,Value
2007,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,94.1
2008,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,95.3
2009,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,95.4
2010,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,96.5
2011,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,95.1
2012,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,96.2
2013,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,96.9
2014,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,95.8
2015,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,96.6
2016,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,96.1
2017,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,93.4
2018,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,94.5
2007,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,93.4
2008,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,96.8
2009,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,95.4
2010,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,96.8
2011,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,96.7
2012,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,98.3
2013,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,97.7
2014,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,98.9
2015,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,98.6
2016,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,98.1
2017,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,96.7
2018,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,96.6
2007,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,93.6
2008,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,95.6
2009,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,95.9
2010,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,95.9
2011,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,94.2
2012,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,95.9
2013,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,97.8
2014,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,94.8
2015,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,96.1
2016,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,95.8
2017,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,93.8
2018,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,96.1
2007,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,93.9
2008,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,95.2
2009,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,95.3
2010,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,97.2
2011,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,93.6
2012,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,96.9
2013,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,97.3
2014,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,91.3
2015,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,98.0
2016,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,95.9
2017,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,96.1
2018,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,95.0
2007,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,94.4
2008,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,95.2
2009,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,95.3
2010,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,96.8
2011,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,95.5
2012,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,97.4
2013,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,98.0
2014,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,97.6
2015,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,97.2
2016,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,96.8
2017,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,97.0
2018,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,94.8
2007,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,94.4
2008,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,94.5
2009,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,95.1
2010,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,95.5
2011,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,93.6
2012,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,93.0
2013,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,96.2
2014,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,98.3
2015,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,97.1
2016,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,98.5
2017,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,96.6
2018,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,95.8
2007,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,94.0
2008,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,94.8
2009,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,94.6
2010,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,96.8
2011,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,95.3
2012,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,96.0
2013,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,96.2
2014,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,93.4
2015,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,96.8
2016,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,95.2
2017,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,93.1
2018,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,95.3
2007,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,94.0
2008,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,95.5
2009,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,95.5
2010,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,96.3
2011,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,96.8
2012,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,97.6
2013,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,96.3
2014,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,96.0
2015,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,97.0
2016,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,97.5
2017,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,91.8
2018,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,92.5
2007,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,95.0
2008,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,94.9
2009,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,95.5
2010,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,96.8
2011,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,96.4
2012,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,97.2
2013,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,96.6
2014,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,93.7
2015,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,94.0
2016,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,90.5
2017,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,86.5
2018,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,90.3
2007,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,95.2
2008,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,96.7
2009,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,95.4
2010,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,95.7
2011,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,95.2
2012,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,98.5
2013,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,99.2
2014,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,96.0
2015,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,97.6
2016,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,96.7
2017,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,98.0
2018,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,95.2
2007,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,98.8
2008,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,99.1
2009,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,98.9
2010,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,98.3
2011,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,97.2
2012,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,97.7
2013,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,98.666102
2014,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,95.6
2015,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,99.1
2016,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,97.0
2017,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,94.7
2018,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,96.244215
2007,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,99.2
2008,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,99.0
2009,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,99.9
2010,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,97.2
2011,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,95.7
2012,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,100.0
2013,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,99.9
2014,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,98.9
2015,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,97.6
2016,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,99.9
2017,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,98.7
2018,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,92.454654
2007,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,97.8
2008,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,99.2
2009,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,98.3
2010,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,98.3
2011,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,100.0
2012,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,99.0
2013,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,99.6
2014,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,91.7
2015,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,100.0
2016,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,95.7
2017,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,88.8
2018,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,93.49863
2007,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,99.0
2008,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,99.7
2009,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,99.7
2010,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,99.2
2011,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,96.9
2012,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,95.7
2013,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,97.4
2014,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,95.6
2015,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,98.9
2016,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,97.7
2017,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,95.1
2018,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,96.51199
2007,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,99.4
2008,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,99.1
2009,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,98.9
2010,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,99.5
2011,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,96.7
2012,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,97.6
2013,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,97.3
2014,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,97.7
2015,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,98.1
2016,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,98.1
2017,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,97.0
2018,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,97.646444
2007,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,98.9
2008,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,99.5
2009,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,99.8
2010,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,99.7
2011,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,94.7
2012,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,96.6
2013,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,97.9
2014,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,96.1
2015,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,99.0
2016,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,99.2
2017,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,96.8
2018,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,98.10916
2007,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,98.6
2008,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,99.2
2009,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.6
2010,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.1
2011,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.7
2012,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,98.8
2013,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.7
2014,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,94.3
2015,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.1
2016,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.0
2017,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,95.6
2018,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,98.413291
2007,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,99.1
2008,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,97.4
2009,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,98.7
2010,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,96.4
2011,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,97.1
2012,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,96.4
2013,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,99.3
2014,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,96.5
2015,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,98.6
2016,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,95.0
2017,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,96.3
2018,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,97.43813
2007,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,99.8
2008,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,99.9
2009,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,98.6
2010,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,99.0
2011,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,97.4
2012,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,97.7
2013,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,98.4
2014,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,95.6
2015,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,99.8
2016,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,95.1
2017,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,91.7
2018,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,96.281062
2007,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,98.8
2008,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,98.9
2009,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,98.2
2010,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,97.4
2011,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,99.7
2012,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,98.1
2013,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,98.7
2014,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,99.9
2015,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,99.7
2016,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,96.8
2017,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,97.7
2018,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,99.425085
2015,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Kyrgyzstan,Percent,96.8
2016,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Kyrgyzstan,Percent,97.2
2017,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Kyrgyzstan,Percent,94.2
2018,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Kyrgyzstan,Percent,92.0
2015,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,Percent,97.3
2016,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,Percent,99.3
2017,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,Percent,96.3
2018,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,Percent,94.6
2015,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,Percent,97.3
2016,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,Percent,95.9
2017,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,Percent,94.5
2018,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,Percent,93.8
2015,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,Percent,98.2
2016,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,Percent,96.4
2017,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,Percent,96.3
2018,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,Percent,95.0
2015,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,Percent,96.8
2016,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,Percent,96.7
2017,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,Percent,97.0
2018,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,Percent,95.1
2015,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,Percent,96.3
2016,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,Percent,98.8
2017,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,Percent,97.2
2018,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,Percent,92.1
2015,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,Percent,97.2
2016,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,Percent,96.1
2017,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,Percent,94.0
2018,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,Percent,96.0
2015,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,Percent,97.6
2016,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,Percent,98.7
2017,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,Percent,92.6
2018,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,Percent,92.1
2015,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),Percent,95.0
2016,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),Percent,94.8
2017,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),Percent,90.4
2018,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),Percent,83.4
2015,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),Percent,97.9
2016,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),Percent,96.8
2017,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),Percent,90.0
2018,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),Percent,93.9
